Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely
The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
FAST NEWS: CanSino’s Covid mRNA Vaccine Approved for Clinical Trials in China
The latest: A new Covid-19 mRNA vaccine developed by CanSino Biologics Inc. (6185.HK) has been approved by China’s National Medical Products Administration to begin clinical trials in the country, the…
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing…
Everest Joins Race to Make mRNA Covid Vaccines for China
Company’s move comes as Beijing shows growing signs of approving the new type of high-tech vaccination Key takeaways: Everest will pay up to $150 million or more to potentially bring…
Recent Articles
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
